# Syno Capital

> Syno Capital is a VC fund in New York backing Medical and Health Care. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 4
- Last investment: Mar 2018
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/6375890
- Website: http://www.synocapital.com

Syno Capital is a principal investment firm focused on life science and healthcare sector investments in New York.

## Contacts

5 contacts available for Syno Capital. Shizune tracks 1 team members at Syno Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/syno-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 75% |
| Health Care | 3 | 75% |
| Biotechnology | 2 | 50% |
| Elder Care | 1 | 25% |
| Life Science | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series A | 1 | 25% |
| Funding Round | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joseph Weilgus | Co-Founder | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TCR2 | TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $125M | Series B | Mar 21, 2018 |  |
| ORIG3N | ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts. | $20M |  | Jun 27, 2017 |  |
| Honor | Honor is the world’s largest senior care network and technology platform. They are fundamentally changing the way we care for parents and loved ones by helping improve the quality of life for more older adults, their families, our Care Professionals, and home care agency owners.In 2021, Honor acquired Home Instead. Honor’s technology andoperations platform, paired with Home Instead’s global network and relationship-based care, enables the combined company to solve how we care for aging adults and professional caregivers around the world.In 2014, Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg co-founded the company in San Francisco, California. | $45M | Series B | Aug 05, 2016 |  |
| ORIG3N | ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts. | $12.5M | Series A | Dec 12, 2015 |  |

4 of 4 investments shown.

## Co-investors
- [180 Degree Capital](https://shizune.co/investors/profile/180-degree-capital) — VC Fund, 2 deals together
- [DEFTA Partners](https://shizune.co/investors/profile/defta-partners) — VC Fund, 2 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 2 deals together
- KTB-KORUS Fund — VC Fund, 2 deals together
- [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 2 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Syno Capital invest in?

Syno Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Syno Capital?

Public channels for Syno Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Syno Capital?

The team at Syno Capital includes Joseph Weilgus (Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co